Pharma Mar (UK) Buy Hold or Sell Recommendation
| 0RC6 Stock | 75.72 2.97 4.08% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Pharma Mar SAU is 'Buy'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Pharma Mar SAU given historical horizon and risk tolerance towards Pharma Mar. When Macroaxis issues a 'buy' or 'sell' recommendation for Pharma Mar SAU, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Pharma Mar Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Pharma and provide practical buy, sell, or hold advice based on investors' constraints. Pharma Mar SAU. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Pharma |
Execute Pharma Mar Buy or Sell Advice
The Pharma recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Pharma Mar SAU. Macroaxis does not own or have any residual interests in Pharma Mar SAU or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Pharma Mar's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Buy
Market Performance | Solid | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Pharma Mar Trading Alerts and Improvement Suggestions
| Pharma Mar SAU appears to be risky and price may revert if volatility continues | |
| Pharma Mar generates negative cash flow from operations | |
| About 21.0% of the company shares are owned by insiders or employees |
Pharma Mar Returns Distribution Density
The distribution of Pharma Mar's historical returns is an attempt to chart the uncertainty of Pharma Mar's future price movements. The chart of the probability distribution of Pharma Mar daily returns describes the distribution of returns around its average expected value. We use Pharma Mar SAU price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Pharma Mar returns is essential to provide solid investment advice for Pharma Mar.
| Mean Return | 1.06 | Value At Risk | -3.43 | Potential Upside | 6.09 | Standard Deviation | 3.77 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Pharma Mar historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Pharma Mar Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (2.4M) | (3.0M) | 1.4M | (17.2M) | (11.5M) | (11.0M) | |
| Change In Cash | (5.1M) | 78.6M | 17.1M | 36.5M | (89.8M) | (85.3M) | |
| Free Cash Flow | (30.0M) | 275.9M | 17.9M | 29.5M | (29.4M) | (27.9M) | |
| Depreciation | 6.1M | 4.3M | 4.6M | 4.9M | 5.8M | 6.1M | |
| Other Non Cash Items | 3.6M | 152.7M | (46.7M) | (20.7M) | 14.3M | 15.0M | |
| Capital Expenditures | 3.9M | 3.0M | 7.8M | 8.9M | 16.0M | 16.8M | |
| Net Income | (23.3M) | 137.3M | 92.9M | 49.4M | 1.1M | 1.2M | |
| End Period Cash Flow | 17.6M | 96.2M | 113.3M | 149.8M | 60.0M | 42.0M | |
| Investments | (19K) | (116.0M) | 26.3M | 19.7M | 22.7M | 23.8M | |
| Net Borrowings | (14.0M) | (31.5M) | (9.4M) | (8.7M) | (7.8M) | (8.2M) | |
| Change To Netincome | (7.3M) | 6.5M | (11.4M) | 11.3M | 13.0M | 13.6M |
Pharma Mar Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Pharma Mar or Commercial Services & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Pharma Mar's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Pharma stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.98 | |
β | Beta against Dow Jones | 0.62 | |
σ | Overall volatility | 3.74 | |
Ir | Information ratio | 0.25 |
Pharma Mar Volatility Alert
Pharma Mar SAU currently demonstrates below-average downside deviation. It has Information Ratio of 0.25 and Jensen Alpha of 0.98. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Pharma Mar's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Pharma Mar's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Pharma Mar Fundamentals Vs Peers
Comparing Pharma Mar's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Pharma Mar's direct or indirect competition across all of the common fundamentals between Pharma Mar and the related equities. This way, we can detect undervalued stocks with similar characteristics as Pharma Mar or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Pharma Mar's fundamental indicators could also be used in its relative valuation, which is a method of valuing Pharma Mar by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Pharma Mar to competition |
| Fundamentals | Pharma Mar | Peer Average |
| Return On Equity | 0.0032 | -0.31 |
| Return On Asset | -0.0065 | -0.14 |
| Profit Margin | 0 % | (1.27) % |
| Operating Margin | 0.12 % | (5.51) % |
| Current Valuation | 1.23 B | 16.62 B |
| Shares Outstanding | 221.28 M | 571.82 M |
| Shares Owned By Insiders | 21.39 % | 10.09 % |
| Shares Owned By Institutions | 7.21 % | 39.21 % |
| Price To Sales | 98.12 X | 11.42 X |
| Revenue | 158.15 M | 9.43 B |
| Gross Profit | 182.7 M | 27.38 B |
| EBITDA | 4.55 M | 3.9 B |
| Net Income | 1.14 M | 570.98 M |
| Total Debt | 43.67 M | 5.32 B |
| Book Value Per Share | 10.39 X | 1.93 K |
| Cash Flow From Operations | (13.45 M) | 971.22 M |
| Earnings Per Share | 5.03 X | 3.12 X |
| Number Of Employees | 509 | 18.84 K |
| Beta | 0.044 | -0.15 |
| Market Capitalization | 16.39 B | 19.03 B |
| Total Asset | 341.22 M | 29.47 B |
| Retained Earnings | 142.22 M | 9.33 B |
| Annual Yield | 0.02 % | |
| Net Asset | 341.22 M | |
| Last Dividend Paid | 0.65 |
Pharma Mar Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Pharma . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Pharma Mar Buy or Sell Advice
When is the right time to buy or sell Pharma Mar SAU? Buying financial instruments such as Pharma Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Pharma Mar in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Business Supplies Thematic Idea Now
Business Supplies
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Business Supplies theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Business Supplies Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Pharma Stock Analysis
When running Pharma Mar's price analysis, check to measure Pharma Mar's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Mar is operating at the current time. Most of Pharma Mar's value examination focuses on studying past and present price action to predict the probability of Pharma Mar's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Mar's price. Additionally, you may evaluate how the addition of Pharma Mar to your portfolios can decrease your overall portfolio volatility.